SAVE Moms and Babies Act of 2025
- Sponsor
- Rep. Latta, Robert E. [R-OH-5]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jan 23, 2025
Bottom line
This bill seeks to significantly restrict access to medication abortion by preventing new drug approvals and imposing stringent new requirements on existing ones, fundamentally altering how these drugs are regulated and accessed.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the Food and Drug Administration (FDA) from approving any new abortion drugs or granting investigational use exemptions for such drugs. It also imposes stringent new regulatory requirements on previously approved abortion drugs, including mandating in-person administration by the prescribing healthcare practitioner, specific practitioner certifications, and enhanced adverse event reporting.
Proponents argue
Supporters argue the bill protects women's health and unborn children by ensuring abortion drugs are administered with appropriate medical oversight, preventing complications from unsupervised use, and reflecting a pro-life stance. They contend it addresses safety concerns associated with remote dispensing and expanded gestational limits, ensuring patients receive comprehensive care.
Opponents contend
Opponents argue the bill severely restricts access to safe and effective medication abortion, undermining patient autonomy and potentially forcing individuals to seek more invasive procedures or travel long distances. They contend it is an ideological attack on reproductive rights, not a genuine safety measure, and that existing FDA regulations are sufficient to ensure patient safety.
The bill is short and relatively straightforward, allowing for a quick understanding of its core provisions and their implications.
Section 2(a), amending 21 U.S.C. 355(aa)(1)(A)
Prohibits FDA Approval of New Abortion Drugs
This provision amends the Federal Food, Drug, and Cosmetic Act to prevent the Food and Drug Administration (FDA) from approving any new applications for marketing abortion drugs. This means no new abortion medications can be introduced to the market in the future, regardless of their potential safety or efficacy improvements.
Supporters argue
Supporters argue this prevents the expansion of abortion access through new drug formulations and aligns with a pro-life agenda to protect unborn life. They may also contend it prevents the introduction of drugs with unknown long-term effects.
Critics contend
Opponents contend this provision stifles medical innovation and limits future options for reproductive healthcare, potentially denying patients access to safer or more effective treatments that could be developed.
Tradeoffs
This provision balances the desire to restrict abortion access with potential impacts on pharmaceutical research and development for reproductive health.
Section 2(a), amending 21 U.S.C. 355(aa)(1)(B) and Section 2(b)
Prohibits Research and Development of Abortion Drugs
This provision prohibits the FDA from granting investigational use exemptions for abortion drugs or for any research that knowingly destroys an unborn child. It also mandates the rescission of existing investigational use exemptions for such drugs after three years from the bill's enactment if they would be prohibited under the new rules. This effectively halts clinical trials and research into new or existing abortion drugs.
Section 2(a), amending 21 U.S.C. 355(aa)(2)(A)
Limits Use and Dispensing of Existing Abortion Drugs
This provision prohibits the FDA from approving any labeling changes for existing abortion drugs that would allow their use after 70 days gestation or permit dispensing by any means other than in-person administration by the prescribing healthcare practitioner. This effectively codifies and tightens existing restrictions on how and when these drugs can be used, preventing expansion of access methods like telehealth or mail-order.
Section 2(a), amending 21 U.S.C. 355(aa)(2)(C)
Mandates Strict REMS for Existing Abortion Drugs
This provision requires all previously approved abortion drugs to be subject to a Risk Evaluation and Mitigation Strategy (REMS) with specific, stringent requirements. These include mandatory certification for prescribing practitioners (requiring abilities to assess pregnancy duration, diagnose ectopic pregnancies, provide surgical intervention for complications, and ensure access to facilities for transfusions/resuscitation), limits on dispensing to in-person administration by the prescriber in a clinic/medical office/hospital (excluding pharmacies), patient documentation of risks, and comprehensive reporting of all adverse events and administration data.
Section 2(a), amending 21 U.S.C. 355(aa)(3)
Mandates Adverse Event Reporting by All Healthcare Practitioners
This provision requires all healthcare practitioners (not just those prescribing abortion drugs) to report any adverse events experienced by their patients that are connected to the use of an abortion drug to the FDA, excluding individually identifiable patient information. This expands the scope of reporting beyond the prescribing physician and manufacturer, aiming for more comprehensive data collection.
Defines "abortion drug" broadly as any drug, substance, or combination intended or used to intentionally kill an unborn child or terminate a pregnancy, irrespective of how the product is labeled, with exceptions for live birth, removing a dead unborn child, or treating an ectopic pregnancy.
Section 2(a), amending 21 U.S.C. 355(aa)(5)(A)
Why it matters:While standard legislative practice to place definitions at the end of a section, the broadness and specific clause 'irrespective of how the product is labeled' are crucial for the bill's scope and could be seen as intentionally broad to prevent workarounds.
Case for: Proponents would argue this broad definition is necessary to prevent manufacturers from relabeling drugs to circumvent the law's intent, ensuring that any drug used for abortion is covered, regardless of its primary or secondary intended use.
Case against: Opponents might argue this broad definition could inadvertently capture drugs with other legitimate medical uses if they are ever used off-label for abortion, potentially leading to unintended restrictions on other medications.
Estimated impact: Significantly broadens the scope of the bill to potentially include drugs not explicitly marketed as abortion drugs, impacting pharmaceutical development and prescribing practices.
Defines "unborn child" as "an individual organism of the species homo sapiens, beginning at fertilization, until the point of being born alive as defined in section 8(b) of title 1, United States Code."
Section 2(a), amending 21 U.S.C. 355(aa)(5)(E)
Why it matters:While standard for definitions, the specific phrasing 'beginning at fertilization' is a key ideological stance that has significant legal and medical implications, often debated in abortion legislation.
Case for: Proponents argue this definition establishes a clear legal and biological starting point for human life, reinforcing the bill's pro-life objectives by extending protections from the moment of conception.
Case against: Opponents contend this definition is a political statement rather than a scientific one, designed to confer personhood from fertilization, which has broad implications beyond abortion drugs, potentially affecting reproductive technologies and research.
Estimated impact: Establishes a legal framework for 'unborn child' that aligns with personhood from conception, impacting legal interpretations of related statutes.